Advertisement

Topics

Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials

03:15 EDT 17 Apr 2018 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
Novartis International AG / Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...